|

Acceptance and Commitment Therapy (ACT-HBC) for the Improvement of Cancer Distress in Patients With Hepatobiliary Cancers

RECRUITINGN/ASponsored by Mayo Clinic
Actively Recruiting
PhaseN/A
SponsorMayo Clinic
Started2025-05-28
Est. completion2027-05-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

This clinical trial studies whether Acceptance and Commitment Therapy for patients with hepatobiliary cancers (ACT-HBC) can be used to help improve cancer distress. Patients with hepatobiliary cancer (HBC) often experience high levels of distress and reductions in quality of life. ACT-HBC is a behavioral intervention tailored to patients with HBC. It helps patients cope with difficult thoughts and emotions while staying connected to what matters most in life, which may be an effective way to improve cancer distress.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* HBC diagnosis
* Age \>= 18 years
* Able to provide written informed consent
* Verbally endorse cancer distress
* Access to the internet
* Read and write in English
* Reside in the states of Iowa, Minnesota, or Wisconsin

Exclusion Criteria:

* Other psychological therapy that started =\< 2 months prior to prospective enrollment
* Inability to actively participate in and learn from group therapy (e.g., active/uncontrolled psychotic symptoms, neurological condition, personality pathology) as determined by clinical judgement in Behavioral Medicine Program (BMP) consultation. Individual therapy or alternative group therapy will be offered to patients ineligible per this criterion
* HBC remission

Conditions2

CancerMalignant Hepatobiliary Neoplasm

Locations1 site

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Sofia Hammel507-255-0760Hammel.Sofia@mayo.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.